A HGF/cMET Autocrine Loop Is Operative in Multiple Myeloma Bone Marrow Endothelial Cells and May Represent a Novel Therapeutic Target

作者：Ferrucci Arianna; Moschetta Michele; Frassanito Maria Antonia; Berardi Simona; Catacchio Ivana; Ria Roberto; Racanelli Vito; Caivano Antonella; Solimando Antonio Giovanni; Vergara Daniele; Maffia Michele; Latorre Dominga; Rizzello Antonia; Zito Alfredo; Ditonno Paolo; Maiorano Eugenio; Ribatti Domenico; Vacca Angelo^*

来源：Clinical Cancer Research, 2014, 20(22): 5796-5807.

DOI：10.1158/1078-0432.CCR-14-0847

Purpose: The aim of this study was to investigate the angiogenic role of the hepatocyte growth factor (HGF)/cMET pathway and its inhibition in bone marrow endothelial cells (EC) from patients with multiple myeloma versus from patients with monoclonal gammopathy of undetermined significance (MGUS) or benign anemia (control group). %26lt;br%26gt;Experimental Design: The HGF/cMET pathway was evaluated in ECs from patients with multiple myeloma (multiple myeloma ECs) at diagnosis, at relapse after bortezomib- or lenalidomide-based therapies, or on refractory phase to these drugs; in ECs from patients with MGUS (MGECs); and in those patients from the control group. The effects of a selective cMET tyrosine kinase inhibitor (SU11274) on multiple myeloma ECs%26apos; angiogenic activities were studied in vitro and in vivo. %26lt;br%26gt;Results: Multiple myeloma ECs express more HGF, cMET, and activated cMET (phospho (p)-cMET) at both RNA and protein levels versus MGECs and control ECs. Multiple myeloma ECs are able to maintain the HGF/cMET pathway activation in absence of external stimulation, whereas treatment with anti-HGF and anti-cMET neutralizing antibodies (Ab) is able to inhibit cMET activation. The cMET pathway regulates several multiple myeloma EC activities, including chemotaxis, motility, adhesion, spreading, and whole angiogenesis. Its inhibition by SU11274 impairs these activities in a statistically significant fashion when combined with bortezomib or lenalidomide, both in vitro and in vivo. %26lt;br%26gt;Conclusions: An autocrine HGF/cMET loop sustains multiple myeloma angiogenesis and represents an appealing new target to potentiate the antiangiogenic management of patients with multiple myeloma.

• 出版日期2014-11-15